PHASEBIO PHARMACEUTICALS INC (PHAS) Stock Price & Overview
NASDAQ:PHAS • US7172241090
Current stock price
The current stock price of PHAS is 0.0701 USD. Today PHAS is down by -26.21%. In the past month the price decreased by -61.78%. In the past year, price decreased by -98.16%.
PHAS Key Statistics
- Market Cap
- 3.495M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.13
- Dividend Yield
- N/A
PHAS Stock Performance
PHAS Stock Chart
PHAS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PHAS. When comparing the yearly performance of all stocks, PHAS is a bad performer in the overall market: 99.57% of all stocks are doing better.
PHAS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAS. Both the profitability and financial health of PHAS have multiple concerns.
PHAS Earnings
PHAS Forecast & Estimates
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
For the next year, analysts expect an EPS growth of 59.21% and a revenue growth -64.49% for PHAS
PHAS Groups
Sector & Classification
PHAS Financial Highlights
Over the last trailing twelve months PHAS reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 36.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -12572.13% | ||
| ROA | -463.95% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PHAS Ownership
PHAS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHAS
Company Profile
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Company Info
IPO: 2018-10-18
PHASEBIO PHARMACEUTICALS INC
1 Great Valley Pkwy Ste 30
Malvern PENNSYLVANIA 19355 US
CEO: Jonathan P. Mow
Employees: 60
Phone: 16109816500.0
PHASEBIO PHARMACEUTICALS INC / PHAS FAQ
What does PHAS do?
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Can you provide the latest stock price for PHASEBIO PHARMACEUTICALS INC?
The current stock price of PHAS is 0.0701 USD. The price decreased by -26.21% in the last trading session.
Does PHAS stock pay dividends?
PHAS does not pay a dividend.
What is the ChartMill rating of PHASEBIO PHARMACEUTICALS INC stock?
PHAS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PHAS stock listed?
PHAS stock is listed on the Nasdaq exchange.
Is PHASEBIO PHARMACEUTICALS INC (PHAS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHAS.
Can you provide the market cap for PHASEBIO PHARMACEUTICALS INC?
PHASEBIO PHARMACEUTICALS INC (PHAS) has a market capitalization of 3.50M USD. This makes PHAS a Nano Cap stock.